CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 100 enrolled
Drug / intervention
Cetylpyridinium Chloride (CPC) +1 moredrug
Likely dose
Cetylpyridinium Chloride (CPC) 1.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02575235
NCT02575235Early Ph 1Completed
CompareCT.gov

Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia

Seoul National University Hospital·interventional·Posted Oct 14, 2015·Updated Oct 8, 2021

In Brief

A Early Phase 1 clinical trial evaluating Cetylpyridinium Chloride (CPC) and placebo for Sarcopenia. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of pre-sarcopenia or sarcopenia over the age of 60

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcopenia
CountriesSouth Korea
Collaborators--

Timeline

Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 14, 2015
Enrollment StartOct 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.7 years ago

Interventions

Cetylpyridinium Chloride (CPC)drug

Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.

placebodrug

Control group takes the placebo for the same period.